Abstract:
A microneedle sheet is disclosed that comprises a plurality of microneedles formed on a sheet generally along a principal surface of the sheet, wherein the microneedles contain a water-soluble polysaccharide and water, the water content is 1 mass % or more and less than 19 mass % based on the total mass of the microneedles, and the microneedles are raised from the principal surface by bending the sheet.
Abstract:
An applicator according to one embodiment is an applicator for applying a sheet member to skin, and includes: a bottom plate facing the skin; a top plate facing the bottom plate and configured to be pressed toward the bottom plate; and a bending portion configured to apply the sheet member to the skin by bending the sheet member having advanced thereto in a pressed state in which the top plate has been moved toward the bottom plate.
Abstract:
A microneedle sheet according to an embodiment comprises a plurality of microneedles formed on a sheet substantially along a principal surface of the sheet. The sheet is bent to raise the microneedles from the principal surface, and the raised microneedles pierce a skin.
Abstract:
A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles, wherein the coating comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and isoproterenol or a pharmaceutically acceptable salt thereof. Using said microneedle device, a fast increase rate of dexmedetomidine concentration in plasma after application of the microneedle device is achieved.
Abstract:
The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.
Abstract:
An adjuvant composition of the present invention contains lauryl alcohol and propylene glycol. Contents of the lauryl alcohol and the propylene glycol are 0.5 to 25% by mass and 8.0 to 99.5% by mass, relative to the total mass of the adjuvant composition, respectively. The lauryl alcohol is dissolved, and the adjuvant composition is used for transdermal or transmucosal administration.
Abstract:
The present invention provides a system for manufacturing a therapeutic microneedle configured to regulate an air environment within a coating chamber for manufacturing a therapeutic microneedle by coating a microneedle with a coating liquid containing a drug, the system for manufacturing a therapeutic microneedle comprising an air compressor, a humidity regulator configured to regulate humidity of air supplied from the air compressor, and an air filter configured to eliminate microorganisms from air to be supplied to the inside of the coating chamber.